Immunomedics (IMMU) Upgraded to Buy by BidaskClub

BidaskClub upgraded shares of Immunomedics (NASDAQ:IMMU) from a hold rating to a buy rating in a research report report published on Friday.

Several other equities analysts have also weighed in on IMMU. Jefferies Group raised their price objective on shares of Immunomedics from $11.00 to $14.00 and gave the company a buy rating in a research report on Tuesday, September 19th. Zacks Investment Research upgraded shares of Immunomedics from a hold rating to a buy rating and set a $15.00 price objective for the company in a research report on Wednesday, October 4th. Finally, ValuEngine lowered shares of Immunomedics from a hold rating to a sell rating in a research report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $15.33.

Immunomedics (NASDAQ:IMMU) traded up $0.84 during trading hours on Friday, hitting $14.65. 3,130,206 shares of the stock traded hands, compared to its average volume of 3,951,401. Immunomedics has a one year low of $3.30 and a one year high of $14.65. The company has a debt-to-equity ratio of -0.29, a quick ratio of 0.74 and a current ratio of 0.74. The company has a market cap of $2,099.41, a price-to-earnings ratio of -6.57 and a beta of 1.51.

In other news, insider Behzad Aghazadeh bought 1,325,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was bought at an average cost of $10.47 per share, for a total transaction of $13,872,750.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian A. Markison sold 8,390 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $11.89, for a total transaction of $99,757.10. Following the completion of the transaction, the director now owns 99,178 shares of the company’s stock, valued at $1,179,226.42. The disclosure for this sale can be found here. Company insiders own 6.60% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Amalgamated Bank boosted its holdings in shares of Immunomedics by 8.1% in the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 966 shares during the period. Stephens Inc. AR acquired a new position in shares of Immunomedics in the second quarter worth about $115,000. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Immunomedics by 11.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,473 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Immunomedics by 99.3% in the second quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 10,323 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of Immunomedics by 7.4% in the second quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 1,747 shares during the period. Institutional investors own 76.28% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/12/23/immunomedics-immu-upgraded-to-buy-by-bidaskclub.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit